Stock INVO INVO BIOSCIENCE, INC.
Add to a list
To use this feature you must be a member
Log inSign up

News INVO Bioscience, Inc.

Equities

INVO

US44984F4019

Market Closed - Nasdaq
Other stock markets
 04:00:00 2024-04-19 pm EDT 		After market 05:12:28 pm
1.37 USD -9.87% Intraday chart for INVO Bioscience, Inc. 1.34 -2.19%
Apr. 18 Top Premarket Decliners MT
Apr. 17 Sector Update: Health Care Stocks Retreating Late Afternoon MT

Summary

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Top Premarket Decliners
MT
Sector Update: Health Care Stocks Retreating Late Afternoon
MT
Top Midday Gainers
MT
Traders Digest Earnings After Rate-Driven Losses, US Equity Futures Rebound Slightly
MT
Top Premarket Gainers
MT
INVO Reports Fourth Quarter and Full Year 2023 Financial Results
AQ
INVO Bioscience : Reports Fourth Quarter and Full Year 2023 Financial Results - Form 8-K
PU
INVO Bioscience, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023
CI
INVO Bioscience, Inc. announced that it has received $0.5 million in funding from FirstFire Capital Management LLC
CI
INVO Bioscience, Inc. announced that it expects to receive $0.5 million in funding from FirstFire Capital Management LLC
CI
INVO Bioscience : Private Placement - Form 8-K
PU
Certain Options of INVO Bioscience, Inc. are subject to a Lock-Up Agreement Ending on 9-FEB-2024.
CI
Certain Warrants of INVO Bioscience, Inc. are subject to a Lock-Up Agreement Ending on 9-FEB-2024.
CI
Certain Common Stock of INVO Bioscience, Inc. are subject to a Lock-Up Agreement Ending on 9-FEB-2024.
CI
INVO Bioscience Files S-4 Registration and Preliminary Joint Proxy Statements in Connection with Merger with NAYA Biosciences, NAYA Announces New Board Directors
AQ
INVO Bioscience, Inc. announced that it expects to receive $5 million in funding from NAYA Biosciences Inc.
CI
INVO Bioscience : Submission of Matters to a Vote of Security Holders - Form 8-K
PU
NAYA Biosciences Announces Publication Of New Data For Its CD38-Targeted Flex-NK Bispecific Antibody in The American Society of Hematology s Blood Journal
AQ
NAYA Biosciences Inc. Announces Publication of New Data for its CD38-targeted Flex-NK Bispecific Antibody in the American Society of Hematology's Blood Journal
CI
INVO Bioscience, Inc. - NAYA Biosciences and ONK Therapeutics Announce Research Partnership to Advance Combination Therapy of FLEX-NK Bispecific Antibodies and Optimally Engineered Off-The-Shelf Natural Killer Cell Therapies
AQ
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. INVO Stock
  4. News INVO Bioscience, Inc.